WO2002057786A3 - Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer - Google Patents

Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer Download PDF

Info

Publication number
WO2002057786A3
WO2002057786A3 PCT/US2002/001189 US0201189W WO02057786A3 WO 2002057786 A3 WO2002057786 A3 WO 2002057786A3 US 0201189 W US0201189 W US 0201189W WO 02057786 A3 WO02057786 A3 WO 02057786A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diagnosis
cancer
compositions
fibronectin fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/001189
Other languages
French (fr)
Other versions
WO2002057786A2 (en
Inventor
Donna Livant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Priority to CA002435320A priority Critical patent/CA2435320C/en
Priority to DE60221115T priority patent/DE60221115T2/en
Priority to EP02713418A priority patent/EP1388013B1/en
Publication of WO2002057786A2 publication Critical patent/WO2002057786A2/en
Anticipated expiration legal-status Critical
Publication of WO2002057786A3 publication Critical patent/WO2002057786A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to the detection tumors in vivo, the imaging of tumors in vivo, and the imaging of cancerous tissue in pathological samples. In particular the present invention incorporates the use of fibronectin fragments into these same detection and imaging methods.
PCT/US2002/001189 2001-01-18 2002-01-15 Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer Ceased WO2002057786A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002435320A CA2435320C (en) 2001-01-18 2002-01-15 Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer
DE60221115T DE60221115T2 (en) 2001-01-18 2002-01-15 COMPOSITIONS AND METHODS FOR USE OF FIBRONECTIN FRAGMENTS IN CANCER DIAGNOSIS
EP02713418A EP1388013B1 (en) 2001-01-18 2002-01-15 Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76549601A 2001-01-18 2001-01-18
US09/765,496 2001-01-18

Publications (2)

Publication Number Publication Date
WO2002057786A2 WO2002057786A2 (en) 2002-07-25
WO2002057786A3 true WO2002057786A3 (en) 2003-12-11

Family

ID=25073705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/001189 Ceased WO2002057786A2 (en) 2001-01-18 2002-01-15 Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer

Country Status (5)

Country Link
EP (1) EP1388013B1 (en)
AT (1) ATE366936T1 (en)
CA (1) CA2435320C (en)
DE (1) DE60221115T2 (en)
WO (1) WO2002057786A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9513298B2 (en) 2004-07-30 2016-12-06 Hologic, Inc. Methods for detecting oncofetal fibronectin

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005545A (en) 2002-11-25 2005-10-18 Attenuon Llc Peptides which target tumor and endothelial cells, compositions and uses thereof.
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc Use of highly parallel snp genotyping for fetal diagnosis
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
EP2058662A1 (en) * 2007-10-17 2009-05-13 Koninklijke Philips Electronics N.V. Diagnosis of diseases by measuring cell mediated extracellular matrix degradation
CA3069082C (en) 2008-09-20 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
EP2182356A1 (en) * 2008-11-04 2010-05-05 Koninklijke Philips Electronics N.V. Use of serum samples for diagnosing prostate cancer by measuring monocyte migration
EP2836843B1 (en) * 2012-04-13 2020-07-08 Prediction Biosciences S.A.S. Rapid test for cellular fibronectin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894326A (en) * 1986-04-09 1990-01-16 Fred Hutchinson Cancer Research Center Monoclonal antibody defining oncofetal structure of fibronectin
US5840514A (en) * 1996-11-21 1998-11-24 The Regents Of The University Of Michigan Methods of testing cancer and anticancer drugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894326A (en) * 1986-04-09 1990-01-16 Fred Hutchinson Cancer Research Center Monoclonal antibody defining oncofetal structure of fibronectin
US5840514A (en) * 1996-11-21 1998-11-24 The Regents Of The University Of Michigan Methods of testing cancer and anticancer drugs

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALBRECHT M ET AL: "Fibronectin in human prostatic cells in vivo and in vitro: Expression, distribution, and pathological significance", HISTOCHEMISTRY AND CELL BIOLOGY, SPRINGER, BERLIN, DE, vol. 112, no. 1, July 1999 (1999-07-01), pages 51 - 61, XP002218305, ISSN: 0948-6143 *
LIVANT D L ET AL: "ANTI-INVASIVE, ANTITUMORIGENIC, AND ANTIMETASTATIC ACTIVITIES OF THE PHSCN SEQUENCE IN PROSTATE CARCINOMA", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 2, 15 January 2000 (2000-01-15), pages 309 - 320, XP001147065, ISSN: 0008-5472 *
LIVANT D L ET AL: "THE PHSRN SEQUENCE INDUCES EXTRACELLULAR MATRIX INVASION AND ACCELERATES WOUND HEALING IN OBESE DIABETIC MICE", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 105, no. 11, June 2000 (2000-06-01), pages 1537 - 1545, XP001147066, ISSN: 0021-9738 *
LIVANT DONNA L ET AL: "Invasion of selectively permeable sea urchin embryo basement membranes by metastatic tumor cells, but not by their normal counterparts.", CANCER RESEARCH, vol. 55, no. 21, 1995, pages 5085 - 5093, XP001147064, ISSN: 0008-5472 *
PELTONEN J ET AL: "FIBRONECTIN GENE EXPRESSION BY EPITHELIAL TUMOR CELLS IN BASAL CELLCARCINOMA: AN IMMUNOCYTOCHEMICAL AND IN SITU HYBRIDIZATION STUDY", JOURNAL OF INVESTIGATIVE DERMATOLOGY, NEW YORK, NY, US, vol. 91, no. 4, October 1988 (1988-10-01), pages 289 - 293, XP000984049, ISSN: 0022-202X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9513298B2 (en) 2004-07-30 2016-12-06 Hologic, Inc. Methods for detecting oncofetal fibronectin

Also Published As

Publication number Publication date
DE60221115T2 (en) 2008-03-13
ATE366936T1 (en) 2007-08-15
EP1388013B1 (en) 2007-07-11
CA2435320A1 (en) 2002-07-25
EP1388013A2 (en) 2004-02-11
DE60221115D1 (en) 2007-08-23
WO2002057786A2 (en) 2002-07-25
CA2435320C (en) 2008-06-03

Similar Documents

Publication Publication Date Title
EP2258872A3 (en) Gene expression profiling in biopsied tumor tissues
EP1892306A3 (en) Methods and kits for investigating cancer
EP2130926A3 (en) Phage microarray profiling of the humoral response to disease
AU2002339865A1 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
WO2003042661A3 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2004008147A3 (en) Diagnosis and prevention of cancer cell invasion
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
CA2352455A1 (en) Methods for stool sample preparation
EP1900827A3 (en) Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2005047534A3 (en) Methods and compositions for the response prediction of malig-nant neoplasia to treatment
WO2002057786A3 (en) Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2007006408A3 (en) Methods and kits for predicting and monitoring direct response to cancer therapy
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
AU2002313726A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
WO2003039484A3 (en) Novel compositions and methods for cancer
AU2002253899A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2006052975A3 (en) Tumor association of mdl-1 and methods
WO2003081250A8 (en) Novel compositions and methods in cancer associated with altered expression of prlr
EP2273271A3 (en) Use of novel biomarkers for detection of testicular carcinoma in situ and derived cancers in human samples

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2435320

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002713418

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002713418

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWG Wipo information: grant in national office

Ref document number: 2002713418

Country of ref document: EP